1-5 of 5
Jan Peter Glossmann
Close
Sort by
Journal Articles

Regular Aspirin Use and Risk of Non-Hodgkin Lymphoma: A Prospective Analysis in the Nurses' Health Study

Elsa Brånvall, MD MPH, Karin E Smedby, MD PhD, Bernard A. Rosner, PhD, Edward Giovannucci, MD ScD, Jan-Peter Glossmann, MD MPH, Kimberly A Bertrand, ScD, Honglei Chen, MD PhD, Francine Laden, ScD, Shumin Zhang, MD ScD, Brenda M. Birmann, ScD
Journal: Blood
Blood (2014) 124 (21): 2990.
https://doi.org/10.1182/blood.V124.21.2990.2990
Published: 2014
Journal Articles

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Bastian von Tresckow, MD, Horst Müller, PhD, Dennis A. Eichenauer, MD, Jan Peter Glossmann, MD, Andreas Josting, MD, Boris Böll, MD, Beate Klimm, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2012) 120 (21): 2633.
https://doi.org/10.1182/blood.V120.21.2633.2633
Published: 2012
Journal Articles

Rituximab Added to an Intensified Salvage Chemotherapy Program Followed by Autologous Stem Cell Transplantation Improve in Relapsed and Refractory Aggressive Non-Hodgkin-Lymphoma.

Michal Sieniawski, MD, Jan-Peter Glossmann, MD, Thorsten Reineke, PhD, Volker Diehl, MD, Andreas Engert, MD, Andreas Josting, MD
Journal: Blood
Blood (2005) 106 (11): 1150.
https://doi.org/10.1182/blood.V106.11.1150.1150
Published: 2005
Journal Articles

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Andreas Josting, MD, Christian Rudolph, MD, Markus Mapara, MD, Jan-Peter Glossmann, MD, Markus Sieber, MD, Hartmut H. Kirchner, MD, Bernd Dörken, MD, Dieter K. Hossfeld, MD, Jens Kisro, MD, Bernd Metzner, MD, Wolfgang E. Berdel, MD, Volker Diehl, MD, Andreas Engert, MD
Journal: Blood
Blood (2004) 104 (11): 309.
https://doi.org/10.1182/blood.V104.11.309.309
Published: 2004
Journal Articles

Comparison of the Sequential High-Dose Chemotherapy Followed by Autologous Stem Cell Support with and without Rituximab in Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma.

Michal Sieniawski, Jan Oliver Staak, Helena Scheuss, Jan Peter Glossmann, Volker Diehl, Andreas Engert, Andreas Josting
Journal: Blood
Blood (2004) 104 (11): 919.
https://doi.org/10.1182/blood.V104.11.919.919
Published: 2004